This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

Novartis AG (NYSE: NVS) recently announced that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Bank of America is the national presenting sponsor and Walgreens, Novartis and Lilly are national series sponsors for the MORE THAN PINK Walk and Race for the Cure events. Join us at the San Antonio ...

In the oncology world, there’s been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years.

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...

The Marie Keating Foundation is marking September being Prostate Cancer Awareness month by launching a new campaign with a ...